Bioprocess Technology Market Size
The Global Bioprocess Technology Market reached USD 93.03 billion in 2025 and is expected to reach USD 228.30 billion by 2033, growing with a CAGR of 11 % during the forecast period 2026-2033.
Bioprocess technology is the industrial application of biological processes involving living cells or their components to effect the desired transformation of substrates. The major advantages of bioprocesses over traditional chemical processes are that they require mild reaction conditions, are more specific and efficient, and produce renewable by-products (biomass). The development of recombinant DNA technology has expanded and extended the potential of bioprocesses.
Bioprocessing or biotechnology is used in the production of pharmaceuticals, foods, flavours, fuels and chemicals with the aid of a biocatalyst such as an enzyme, microorganisms, plant cell, or animal cell in a bioreactor. It also involves genetic engineering for the manipulation of plants, animals, and microorganisms such as yeasts, bacteria and fungi.
Market Scope
| Metrics | Details |
| CAGR | High |
| Size Available for Years | 2025-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$ Mn) |
| Segments Covered | Product Type, Consumables and Accessories, Application, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics
Rise in investments in research and development by biotechnology and pharmaceutical companies
The rise in investments in research and development by biotechnology and pharmaceutical companies is one of the key factors that helps the market to grow during the forecast period. Because of the transition of pharmaceutical firms towards biotechnology, which has created development potential, the biopharmaceutical industry has strengthened its roots across the medical and pharmaceutical industries.
For instance, an article published in the Biotechnology Report in July 2022 stated that growing technological developments in biopharmaceutical and pharmaceutical sectors like 3D bioprinting, biosensors, and gene editing, as well as the incorporation of cutting-edge artificial intelligence and virtual and augmented reality, are expected to open growth opportunities by increasing and speeding the production through bioprocessing.
Reported they had entered into a definitive business combination agreement. This agreement is to accelerate the development of Oculis' differentiated ophthalmology pipeline. This product addresses areas of significant medical need, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications, such as glaucoma, affecting growing patient populations.
Furthermore, an increase in the funding for research and development of bioprocessing technology is estimated to propel the growth of the global bioprocess market. Continuous technological advancements in the bioprocess Moreover, increasing support from the governments of various countries in terms of biofuel production is further expected to drive the growth of the bioprocess technology market.
Restraint
Strict regulations are one of the factors that hamper the market growth during the forecast period. The market players in the bioprocess technology sector find it difficult to advance at the growth pace. Many governments around the world have already taken action, and some of them are choosing to impose severe regulation policies backed by the high cost of the market instruments that are preventing the market from expanding during the projected period. Also, the high cost of technology and lack of skilled professionals are the factors that hamper the market growth during the forecast period.
Segmentation Analysis
The global bioprocess technology is segmented based on product type, consumables and accessories, application, end-user and region.
The bioreactors from the product type
A bioreactor is an indispensable part of any bioprocess irrespective of whether the process degrades pollutants or produces substances such as foods, feeds, chemicals and pharmaceuticals, and tissues and organs for use in biomedicine.
The goal is to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers, according to both companies.
Moreover, The firm is developing its microfluidics-based bioreactor using its proprietary self-developed Brick Printing Technology which powers its Sclereid 3D printer. According to Stämm, the 3D printer’s capabilities could extend to building the installed capacity of bioreactors worldwide for biopharma in just one year.
Geographical Share
The high prevalence of chronic diseases that mostly use biopharmaceuticals for treatments and the established healthcare infrastructure in the region has significantly contributed to the industry growth.
This automated integration removes error-prone manual steps while enabling load-and-go sample runs for up to eight bioreactors, GMP compliance with electronic data management, and continuous control of viable cell density, including remote workflows.
Market Companies
The major global players in bioprocess technology market include Thermo Fisher Scientific Inc., Sartorius, Roche, Repligen, Merck, SolidaBiotech, Univercellstech, Advanced Instruments, ELITechGroup Inc, Cytiva and among others.
Recent Developments
- February 2026 - New bioprocess scale-up center launched to accelerate industrial biotechnology development.
German process technology company Glatt partnered with PreferCo to establish a bioprocess scale-up center in Genome Valley, Hyderabad. The facility supports precision fermentation and microbial bioprocess development with pilot-scale reactors up to 1,500 L capacity. Advanced automation, AI-enabled process monitoring, and digital control systems are integrated to improve process reproducibility and reduce commercialization risks. This initiative strengthens infrastructure for biopharmaceuticals, bio-based chemicals, and sustainable materials production. - January 2026 - Continuous bioprocessing technologies gain traction in commercial biologics manufacturing.
Biopharmaceutical companies are increasingly adopting continuous bioprocessing systems to improve production efficiency and yield. Platforms such as WuXiUP have demonstrated high-productivity output during extended production runs, while manufacturers are integrating automation and advanced monitoring to maintain product quality. These technologies enable higher productivity compared with traditional batch processes and support large-scale biologics manufacturing. - December 2025 - Rapid sterility testing and advanced bioreactor platforms enhance bioprocess productivity.
Bioprocess technology providers are introducing advanced single-use bioreactors and rapid sterility testing tools to improve manufacturing efficiency. For example, Thermo Fisher Scientific introduced rapid microbial testing technologies capable of delivering sterility results in less than one day, helping accelerate biopharmaceutical production timelines and ensuring regulatory compliance. - November 2025 - India launches single-use bioprocess design and scale-up hub to support biologics innovation.
Genome Valley in Hyderabad unveiled 1 Bio, the country’s first dedicated single-use bioprocess design and scale-up facility. The hub provides infrastructure for developing next-generation biologics and advanced therapeutics, strengthening India’s position in global biomanufacturing and supporting research organizations working on complex biologic products. - October 2025 - Increasing adoption of single-use bioprocessing technologies across biopharmaceutical manufacturing.
Biopharmaceutical companies are expanding the use of disposable bioprocess systems such as single-use bioreactors, tubing, and filtration assemblies to reduce contamination risks and lower operational costs. These systems allow faster facility setup, simplified sterilization processes, and improved flexibility in biologics production, making them increasingly preferred in modern biomanufacturing facilities.
Why Purchase the Report?
- To visualize the global bioprocess technology market segmentation-based product type, consumables and accessories, application, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous bioprocess technology market-level data points with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global bioprocess technology market report would provide approximately 69 tables, 70 figures, and 185 Pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
